高钾血症 中国就医指南

Hyperkalemia is a potentially life-threatening endocrine and metabolic disorder characterized by an elevated serum potassium concentration exceeding 5.0 mmol/L. As potassium is a critical electrolyte for cardiac conduction, neuromuscular excitability, and cellular homeostasis, even mild-to-moderate elevations (5.1–6.0 mmol/L) can cause palpitations, muscle weakness, and fatigue; severe hyperkalemia (>6.5 mmol/L) may precipitate fatal cardiac arrhythmias—including peaked T-waves, loss of P-waves, widened QRS complexes, ventricular fibrillation, or asystole—requiring immediate intervention. Pathophysiologically, hyperkalemia arises from one or more imbalances: impaired renal potassium excretion (most commonly due to chronic kidney disease, acute kidney injury, or hypoaldosteronism), excessive potassium intake (e.g., salt substitutes, IV potassium, or high-potassium diets in susceptible individuals), or transcellular shifts (e.g., acidosis, insulin deficiency in diabetes, rhabdomyolysis, hemolysis, or beta-blocker use). Medications such as ACE inhibitors, ARBs, potassium-sparing diuretics (e.g., spironolactone), NSAIDs, and trimethoprim significantly increase risk—especially in older adults or those with comorbidities like heart failure or diabetes. Epidemiologically, hyperkalemia affects approximately 2–10% of hospitalized patients, with prevalence rising to 20–30% among those with advanced chronic kidney disease (CKD Stage 4–5) or heart failure on renin-angiotensin-aldosterone system (RAAS) inhibitors. Community prevalence is lower (<1%), but underdiagnosed due to asymptomatic presentation in early stages. Key risk factors include CKD, diabetes mellitus, adrenal insufficiency, congestive heart failure, liver cirrhosis, advanced age (>75 years), polypharmacy, and dietary nonadherence to low-potassium regimens. Quality of life is substantially impacted—not only through acute symptoms like generalized weakness, nausea, and anxiety about sudden cardiac events, but also via long-term burdens: frequent blood monitoring, strict dietary restrictions (limiting bananas, potatoes, tomatoes, dairy, and processed foods), medication adjustments, hospital readmissions, and psychological distress related to disease unpredictability and treatment complexity. Patients often report reduced physical stamina, social isolation due to dietary limitations, and diminished confidence in managing daily activities without triggering episodes. Early recognition, multidisciplinary care involving endocrinologists, nephrologists, and dietitians, and individualized prevention strategies are essential to mitigate morbidity and improve functional outcomes.

# 高钾血症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：血钾5.1–6.0 mmol/L、无心电图改变、肾功能稳定者

• •药物治疗：

- 静脉胰岛素+葡萄糖（10U胰岛素+50ml 50%GS）：85–120元/次 - β₂受体激动剂雾化（沙丁胺醇）：60–95元/次

• •检验费：电解质+肌酐+心电图（急诊加急）：128–165元

二、紧急干预/血液净化方案

适用人群：血钾＞6.5 mmol/L、T波高尖/室性心律失常、急性肾损伤者

• •血液透析（单次）：含管路耗材、抗凝、监护：2,800–3,600元/次
• •连续性肾脏替代治疗（CRRT，24h）：5,200–6,800元/日
• •术前检查（凝血四项、血型、传染病筛查、血管通路评估）：420–580元

三、特殊复杂情况处理

适用人群：顽固性高钾（反复发作）、终末期肾病合并严重代谢性酸中毒、ACEI/ARB长期用药难停者

• •多学科联合管理（内分泌+肾内科+药学部）：首诊评估费 300元；月度随访管理费 600–900元
• •新型钾结合剂（环硅酸锆钠）：3,200–4,500元/盒（30g，约10天用量）

方案快速选择指南

• •预算＜500元/次、轻症初发：首选口服降钾药+电解质监测（总费用≤450元）
• •中重度（K⁺≥6.0）、需当日干预：静脉胰岛素+透析准备，总费用约3,000–4,000元
• •慢性复发/ESRD患者：CRRT联合新型钾结合剂，月均支出约12,000–18,000元